Langer-inspired Kala files for an $86M IPO; J&J backs Provention Bio
→ Kala Pharmaceuticals has filed for an $86 million IPO, just weeks after the biotech reported positive top line data for a Phase III study of its lead ophthalmology drug KPI-121. In its S-1 the biotech — co-founded by MIT’s Bob Langer — says that it will file its first NDA before the end of this year, with another to follow in early 2018. And it’s in two more Phase III studies for dry eye disease with another formulation of the lead treatment. Kala has tried to pull off an IPO during trying times for biotech stocks. Now the market has been booming for a few days at least and biotech IPOs have been lining up to take advantage of growing evidence that investors are once again investing in risky plays.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.